Monitor whether the concurrent convertible note offering closes, as this could add significant future dilution. The substantial dilution for new investors suggests caution, though the capital infusion strengthens the company's R&D runway.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $1.88entry
- T+1 · 7mo ago 0.00%α −1.21% · $1.88
- T+5 · 7mo ago 0.00%α −0.98% · $1.88
- T+20 · 6mo ago 0.00%α −5.82% · $1.88
- T+60 · 4mo ago +376.60%α +369.55% · $8.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines is raising $1.44 billion through a public offering of 10.56 million common shares at $142.00 per share, alongside a concurrent $500 million convertible note offering. The proceeds will fund R&D and general corporate purposes.
Key Facts
- Offering 10,563,381 shares of common stock at $142.00 per share, raising $1.44 billion in gross proceeds
- Concurrent offering of $500 million in 0.50% convertible senior notes due 2033
- Net proceeds estimated at $1.435 billion after underwriting discounts and expenses
- Proceeds to be used for R&D, potential commercialization, general corporate purposes, and possible acquisitions
- Significant dilution for new investors: $127.57 per share based on $7.92 book value vs. $142.00 offering price
Financial Impact
$1.44 billion raised from equity offering and $500 million from convertible notes
Risk Factors
- Immediate and substantial dilution for new investors
- Potential for additional dilution from the concurrent $500 million convertible note offering
- Future sales from the $1 billion ATM program could pressure stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-157273 |
| Document: d93698dexfilingfees.htm | 0001193125-26-157273 |
| Document: 0001193125-26-157273-index-headers.html | 0001193125-26-157273 |
| Document: 0001193125-26-157273-index.html | 0001193125-26-157273 |
| Document: 0001193125-26-157273.txt | 0001193125-26-157273 |
Track record
8 reports on RVMDW
0 of 3 bullish or bearish reports moved the stock their way by T+60. Best: 0.00% at T+1 after the Apr 15, 2026 report. 0 of 3 went positive at some point.
Filters
- Apr 17, 202630w ago 8-K Bearish 8/10 Entry $1.88 to $9.07 ▼ −382.45% −375.67% vs SPY
- Apr 16, 202630w ago 8-K Neutral 6/10 Entry $1.88 to $8.98 ▲ +377.66% +371.52% vs SPY
- Apr 15, 202630w ago 424B5 Neutral 6/10 Viewing Entry $1.88 to $8.96 ▲ +376.60% +369.55% vs SPY
- Apr 15, 202630w ago 424B5 Bearish 7/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 15, 202630w ago 144 Bearish 6/10 Entry $1.88 to $8.96 ▼ −376.60% −369.55% vs SPY
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 424B5 Bearish 7/10 Entry $1.88 No price data
- Apr 13, 202631w ago 8-K Bullish 8/10 Entry $1.88 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers